🚀 VC round data is live in beta, check it out!
Harrow Valuation Multiples
Discover revenue and EBITDA valuation multiples for Harrow and similar public comparables like Phibro Animal Health, Cheezheng Tibetan Medicine, Aurinia Pharmaceuticals, Eris Lifesciences and more.
Harrow Overview
About Harrow
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company’s FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company’s ophthalmology-focused pharmaceutical compounding business.
Founded
2006
HQ
Employees
382
Website
Sectors
Financials (LTM)
EV
$2B
Harrow Financials
Harrow reported last 12-month revenue of $293M and EBITDA of $70M.
In the same LTM period, Harrow generated $222M in gross profit, $70M in EBITDA, and $2M in net income.
Revenue (LTM)
Harrow P&L
In the most recent fiscal year, Harrow reported revenue of $272M and EBITDA of $62M.
Harrow expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $293M | XXX | $272M | XXX | XXX | XXX |
| Gross Profit | $222M | XXX | $204M | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $70M | XXX | $62M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 23% | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $2M | XXX | ($5M) | XXX | XXX | XXX |
| Net Margin | 1% | XXX | (2%) | XXX | XXX | XXX |
| Net Debt | — | — | $170M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Harrow Stock Performance
Harrow has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Harrow's stock price is $54.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $-0.14 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHarrow Valuation Multiples
Harrow trades at 7.4x EV/Revenue multiple, and 31.1x EV/EBITDA.
EV / Revenue (LTM)
Harrow Financial Valuation Multiples
As of March 21, 2026, Harrow has market cap of $2B and EV of $2B.
Equity research analysts estimate Harrow's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Harrow has a P/E ratio of 826.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 7.4x | XXX | 8.0x | XXX | XXX | XXX |
| EV/EBITDA | 31.1x | XXX | 35.3x | XXX | XXX | XXX |
| EV/EBIT | 60.5x | XXX | 71.6x | XXX | XXX | XXX |
| EV/Gross Profit | 9.8x | XXX | 10.7x | XXX | XXX | XXX |
| P/E | 826.4x | XXX | (390.5x) | XXX | XXX | XXX |
| EV/FCF | 49.8x | XXX | 51.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Harrow Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Harrow Margins & Growth Rates
Harrow's revenue in the last 12 month grew by 39%.
Harrow's revenue per employee in the last FY averaged $0.8M.
Harrow's rule of 40 is 62% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Harrow's rule of X is 120% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Harrow Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 39% | XXX | 36% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 71% | XXX | 62% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 62% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 120% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 64% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Harrow Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Phibro Animal Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Cheezheng Tibetan Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Aurinia Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Eris Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Nuvation Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Harrow M&A Activity
Harrow acquired XXX companies to date.
Last acquisition by Harrow was on XXXXXXXX, XXXXX. Harrow acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Harrow
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHarrow Investment Activity
Harrow invested in XXX companies to date.
Harrow made its latest investment on XXXXXXXX, XXXXX. Harrow invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Harrow
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Harrow
| When was Harrow founded? | Harrow was founded in 2006. |
| Where is Harrow headquartered? | Harrow is headquartered in United States. |
| How many employees does Harrow have? | As of today, Harrow has over 382 employees. |
| Who is the CEO of Harrow? | Harrow's CEO is Mark L. Baum. |
| Is Harrow publicly listed? | Yes, Harrow is a public company listed on Nasdaq. |
| What is the stock symbol of Harrow? | Harrow trades under HROW ticker. |
| When did Harrow go public? | Harrow went public in 2007. |
| Who are competitors of Harrow? | Harrow main competitors are Phibro Animal Health, Cheezheng Tibetan Medicine, Aurinia Pharmaceuticals, Eris Lifesciences. |
| What is the current market cap of Harrow? | Harrow's current market cap is $2B. |
| What is the current revenue of Harrow? | Harrow's last 12 months revenue is $293M. |
| What is the current revenue growth of Harrow? | Harrow revenue growth (NTM/LTM) is 39%. |
| What is the current EV/Revenue multiple of Harrow? | Current revenue multiple of Harrow is 7.4x. |
| Is Harrow profitable? | Yes, Harrow is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Harrow? | Harrow's last 12 months EBITDA is $70M. |
| What is Harrow's EBITDA margin? | Harrow's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Harrow? | Current EBITDA multiple of Harrow is 31.1x. |
| What is the current FCF of Harrow? | Harrow's last 12 months FCF is $44M. |
| What is Harrow's FCF margin? | Harrow's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Harrow? | Current FCF multiple of Harrow is 49.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.